Developing treatments for rare diseases is already risky and expensive, and the COVID-19 pandemic made it even harder — disrupting clinical trials and slowing down research timelines. This bill, named "Leo's Law," would give orphan drug developers (companies working on treatments for rare diseases) an extra 180 days of market exclusivity to make up for pandemic-related delays. That means more time before generic or biosimilar competitors can enter the market, which could help incentivize continued investment in treatments that often serve very small patient populations.
Corporate Benefits
- Orphan-drug market exclusivity — Extended by 180 days for drugs developed during the COVID-19 emergency period
- Biosimilar exclusivity periods — 12-year and 4-year windows extended by 180 days for covered orphan biologics
- Patent-related approval-delay periods — Corresponding 30-month and related stay periods extended by 180 days
Average Household Impact
- Generic and biosimilar entry timeline — Pushed back 180 days for covered rare-disease drugs
Congressional Summary
Leo's Law This bill extends by 180 days the relevant periods of market exclusivity for drugs for rare diseases or conditions (i.e., orphan drugs) for which applications were submitted during the COVID-19 emergency period.
Details
- Congress
- 119th
- Chamber
- House
- Status
- summarized
- Action
- Introduced in House
- Action Date
- 2026-02-25
- Date Added
- 2026-04-06
- Source
- Congress.gov →
Like reading a bill in plain English?
We're building an app that does this for every bill in Congress and lets you tell your reps how you want them to vote. We're a small team getting ready to launch, and we're trying to show investors that real people want this. Be one of them. Help us get it built. Leave your email and we'll tell you the moment the app is ready.